Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lung cancer].

Hiroshi Komagata1, Shuichi Yoneda

  • 1Division of Respiratory Disease, Saitama Cancer Center.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 29, 2004
PubMed
Summary
This summary is machine-generated.

This review covers six key lung cancer tumor markers: CEA, SLX, CYFRA, SCC, ProGRP, and NSE. While not definitive, these markers are crucial supporting tools in daily medical oncology for assessing cancer status and monitoring therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrence of cardiovascular events despite achieving LDL-C <1.4 mmol/L in patients with coronary artery disease.

Journal of clinical lipidology·2026
Same author

Optimization strategies for percutaneous coronary intervention in calcified coronary lesions: current evidence and future directions.

Expert review of cardiovascular therapy·2026
Same author

Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals.

European heart journal·2026
Same author

Achieving LDL-C <1.0 mmol/L and cardiovascular outcomes in patients with coronary artery disease who received percutaneous coronary intervention.

Atherosclerosis·2026
Same author

Achieved LDL-C levels <55 mg/dL and cardiac events in patients and lesions harbouring lipid-rich plaque phenotypes.

European heart journal. Cardiovascular Imaging·2026
Same author

Enhanced Efficacy of Rotational Atherectomy for Calcified Nodules With Contralateral Calcification: Insights From a Multicenter Intravascular Ultrasound Imaging Study.

Circulation. Cardiovascular interventions·2026
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Biochemistry
  • Medical Diagnostics

Background:

  • Tumor markers are substances indicating cancer presence, characteristics, and volume.
  • They aid in assessing cancer presence, site, histology, stage, recurrence, and therapy response.
  • For lung cancer, markers have supporting roles due to limitations in sensitivity and specificity.

Purpose of the Study:

  • To review six significant tumor markers used in lung cancer diagnosis and management.
  • To highlight the clinical importance of these markers in daily medical oncology.

Main Methods:

  • Literature review of established tumor markers for lung cancer.
  • Focus on Carcinoembryonic Antigen (CEA), Squamous Cell Carcinoma Antigen (SCC), CYFRA 21-1 (CYFRA), Surfactant Level X (SLX), Pro-Gastrin-Releasing Peptide (ProGRP), and Neuron-Specific Enolase (NSE).

Related Experiment Videos

Main Results:

  • The review details the utility of CEA, SLX, CYFRA, SCC, ProGRP, and NSE in lung cancer assessment.
  • These markers provide essential supportive data in clinical oncology practice.
  • Acknowledges limitations in sensitivity and specificity for these lung cancer markers.

Conclusions:

  • Despite limitations, the discussed tumor markers are clinically indispensable in lung cancer management.
  • They play a vital supporting role in patient diagnosis, staging, and therapeutic monitoring.
  • Further research may enhance the sensitivity and specificity of these diagnostic tools.